Maasstad Ziekenhuis

Running trials

• Not yet recruiting

  Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.

  NCT07860775· Phase 2· Source

• Recruiting

  HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment

  2025-524283-38-00· Phase 3· Source

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Source

• Not yet recruiting

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· Phase 3· Source

• Not yet recruiting

  A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)

  2025-524005-32-00· Phase 2· Source

• Enrolling by invitation

  Coronary Sinus Reducer in Coronary Microvascular Disease

  NCT06898541· Source

• Recruiting

  NO Re-excision MelanomA - NORMA 2

  NCT07530887· Phase 3· Source

• Recruiting

  ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

  NCT07188025· Phase 3· Source

• Recruiting

  #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.

  NCT06900829· Source

• Recruiting

  A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

  NCT07133633· Phase 2· Source

• Recruiting

  REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases

  NCT07160231· Phase 4· Source

• Recruiting

  StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial

  2024-517343-31-00· Phase 4· Source

• Active, not recruiting

  Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients (PSMA-SELECT).

  2024-518171-59-00· Phase 4· Source

• Recruiting

  Tocilizumab Dose Optimization in Rheumatoid Arthritis

  2025-520513-30-00· Phase 4· Source

• Recruiting

  Optimizing therapy with n=1-studies: negating the 'nocebo' effect in statin-intolerance

  2023-507489-20-00· Phase 4· Source

• Recruiting

  Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial

  2024-513092-40-00· Phase 4· Source

• Active, not recruiting

  Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

  NCT06543914· Source

• Recruiting

  DAROTAXEL

  2024-516939-28-00· Phase 2· Source

• Active, not recruiting

  Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NVALT-30 - Dedication-1)

  NCT04909684· Phase 3· Source

• Active, not recruiting

  Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)

  NCT04225312· Phase 4· Source

• Recruiting

  DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

  NCT06275958· Phase 3· Source

• Recruiting

  Pro-RAPID

  NCT05552287· Phase 4· Source

• Recruiting

  FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

  NCT06187441· Phase 3· Source

• Recruiting

  A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS

  NCT06189833· Phase 2· Source

• Recruiting

  The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients

  NCT06082492· Source

• Recruiting

  Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer

  NCT07260435· Phase 3· Source

• Recruiting

  Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume castration-sensitive prostate cancer: a randomized Nationwide Study

  2023-506698-36-00· Phase 3· Source

• Recruiting

  A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Subjects with Suspected Coronary Artery Disease

  2023-506971-89-00· Phase 3· Source

• Recruiting

  PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)

  NCT06875258· Phase 4· Source

• Active, not recruiting

  PEHAB II

  2023-507466-40-00· Phase 4· Source

• Active, not recruiting

  Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS

  2022-502664-21-00· Phase 4· Source

• Active, not recruiting

  Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

  NCT05705973· Source

• Not yet recruiting

  COATS (genetic Clopidogrel response testing to finetune the antithrombotic regimen in (D)OAC Treated patients undergoing PCI) Study

  2024-512350-17-01· Phase 4· Source

• Recruiting

  High-Risk prostatE Cancer radiatiOn Versus surgERy

  NCT05931419· Source

• Recruiting

  National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)

  NCT05326620· Source

• Active, not recruiting

  The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

  NCT05374291· Phase 3· Source

• Active, not recruiting

  The Euro-CRAFT Registry

  NCT05805462· Source

• Active, not recruiting

  Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  NCT05243797· Phase 3· Source

• Active, not recruiting

  SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)

  NCT05392608· Phase 2· Source

• Active, not recruiting

  Personalized dosing of ocrelizumab in MS

  2024-513193-22-00· Phase 4· Source

• Recruiting

  Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study

  NCT04973397· Source

• Recruiting

  The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent

  NCT04923191· Source

• Active, not recruiting

  Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

  NCT04927780· Phase 3· Source

• Active, not recruiting

  Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

  NCT04608318· Phase 3· Source

• Recruiting

  REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

  NCT04523428· Phase 2· Source

• Enrolling by invitation

  The NetherLands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT)

  NCT06083155· Source

• Recruiting

  Evaluating, clinical and immunological effects of rituximab with cyclophosphamide compared to rituximab alone in AAV patients

  2023-507868-39-00· Phase 4· Source

• Active, not recruiting

  Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

  NCT03833154· Phase 3· Source

• Active, not recruiting

  The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

  NCT03463057· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease7 recruiting
• Prostate cancer5 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Colorectal cancer3 recruiting
• Rheumatoid arthritis3 recruiting
• Ankylosing spondylitis2 recruiting
• Stroke2 recruiting
• ANCA-associated vasculitis1 recruiting
• Childhood cancers1 recruiting
• Crohn's disease1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Heart failure1 recruiting
• HIV1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Obesity1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Sjögren's disease1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study With CIT-013 in RA Patients

  NCT06567470· Phase 2· Source

• Completed

  THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER (PREOPANC-2 STUDY)

  2024-516260-29-00· Phase 3· Source

• Completed

  Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point of view. Tailoring of treatment is done by taking the presence of autoantibodies and the quick response to glucocorticoids and JAK inhibitors into account.

  2024-511530-12-01· Phase 4· Source

• Active, not recruiting

  Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

  NCT06293365· Phase 2· Source

• Completed

  Effect of Music Prehabilitation on Preoperative Anxiety Before Surgery

  NCT05982184· Source

• Completed

  A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

  NCT05911360· Phase 3· Source

• Completed

  A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter

  NCT05828173· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Source

• Completed

  Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy

  NCT04657120· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· Source

• Completed

  PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

  NCT03168776· Source

• Completed

  A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations, HOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups

  NCT03226301· Phase 2· Source

• Completed

  A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

  NCT03104374· Phase 3· Source

• Completed

  A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

  NCT03104400· Phase 3· Source

• Completed

  Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

  NCT02947347· Phase 3· Source

• Completed

  autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

  2024-511235-10-00· Phase 3· Source

• Completed

  Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

  NCT02162563· Phase 3· Source

Trial sites

• 5280018 - Maasstad Ziekenhuis1 trial
• Maasstad Ziekenhuis22 trials
• Maasstad Ziekenhuis - Cardiologie0 trials
• Maasstad Ziekenhuis /ID# 1601681 trial
• Maasstad Ziekenhuis /ID# 1630501 trial
• Maasstad Ziekenhuis /ID# 2696011 trial
• Maasstad Ziekenhuis Rotterdam1 trial
• Maasstad Ziekenhuis (Site 1102)0 trials
• Maasstad Ziekenhuis Stichting46 trials
• Stichting Maasstad Ziekenhuis4 trials